Biosignatures: Comparative effectiveness research in biomarker clinical studies

Due to increased healthcare expenditure and the need for evidence-supported clinical decision-making, clinical evaluation using comparative effectiveness research (CER) was initially proposed in the US. CER consists of generating and synthesizing evidence in relative benefits, harms, and costs of di...

Full description

Bibliographic Details
Main Authors: Jur-Shan Cheng, David Bin-Shiun Wu, Yu Wen Wen, Pi-Hua Liu, Jr-Rung Lin, Chee-Jen Chang
Format: Article
Language:English
Published: Elsevier 2012-06-01
Series:Journal of the Formosan Medical Association
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S0929664612001441
id doaj-72738c8955384c1bbec044aa094a44ba
record_format Article
spelling doaj-72738c8955384c1bbec044aa094a44ba2020-11-24T23:06:23ZengElsevierJournal of the Formosan Medical Association0929-66462012-06-01111630030410.1016/j.jfma.2011.12.011Biosignatures: Comparative effectiveness research in biomarker clinical studiesJur-Shan Cheng0David Bin-Shiun Wu1Yu Wen Wen2Pi-Hua Liu3Jr-Rung Lin4Chee-Jen Chang5Clinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan, TaiwanDivision of Biostatistics, Institute of Public Health, National Yang Ming University, Taipei, TaiwanClinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan, TaiwanClinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan, TaiwanClinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan, TaiwanClinical Informatics and Medical Statistics Research Center, Chang Gung University, Taoyuan, TaiwanDue to increased healthcare expenditure and the need for evidence-supported clinical decision-making, clinical evaluation using comparative effectiveness research (CER) was initially proposed in the US. CER consists of generating and synthesizing evidence in relative benefits, harms, and costs of different alternatives through direct head-to-head comparisons. CER studies can help identify the most effective interventions for patients under specific circumstances, and therefore improve the efficiency of the healthcare system. A Biosignatures project newly launched in Taiwan was inspired by CER, aiming at using discovered biomarkers panel as tools in early detection of disease and prediction of treatment effectiveness.http://www.sciencedirect.com/science/article/pii/S0929664612001441biomarkerbiosignaturescomparative effectiveness research (CER)evidence based medicine (EBM)randomized clinical trials (RCT)
collection DOAJ
language English
format Article
sources DOAJ
author Jur-Shan Cheng
David Bin-Shiun Wu
Yu Wen Wen
Pi-Hua Liu
Jr-Rung Lin
Chee-Jen Chang
spellingShingle Jur-Shan Cheng
David Bin-Shiun Wu
Yu Wen Wen
Pi-Hua Liu
Jr-Rung Lin
Chee-Jen Chang
Biosignatures: Comparative effectiveness research in biomarker clinical studies
Journal of the Formosan Medical Association
biomarker
biosignatures
comparative effectiveness research (CER)
evidence based medicine (EBM)
randomized clinical trials (RCT)
author_facet Jur-Shan Cheng
David Bin-Shiun Wu
Yu Wen Wen
Pi-Hua Liu
Jr-Rung Lin
Chee-Jen Chang
author_sort Jur-Shan Cheng
title Biosignatures: Comparative effectiveness research in biomarker clinical studies
title_short Biosignatures: Comparative effectiveness research in biomarker clinical studies
title_full Biosignatures: Comparative effectiveness research in biomarker clinical studies
title_fullStr Biosignatures: Comparative effectiveness research in biomarker clinical studies
title_full_unstemmed Biosignatures: Comparative effectiveness research in biomarker clinical studies
title_sort biosignatures: comparative effectiveness research in biomarker clinical studies
publisher Elsevier
series Journal of the Formosan Medical Association
issn 0929-6646
publishDate 2012-06-01
description Due to increased healthcare expenditure and the need for evidence-supported clinical decision-making, clinical evaluation using comparative effectiveness research (CER) was initially proposed in the US. CER consists of generating and synthesizing evidence in relative benefits, harms, and costs of different alternatives through direct head-to-head comparisons. CER studies can help identify the most effective interventions for patients under specific circumstances, and therefore improve the efficiency of the healthcare system. A Biosignatures project newly launched in Taiwan was inspired by CER, aiming at using discovered biomarkers panel as tools in early detection of disease and prediction of treatment effectiveness.
topic biomarker
biosignatures
comparative effectiveness research (CER)
evidence based medicine (EBM)
randomized clinical trials (RCT)
url http://www.sciencedirect.com/science/article/pii/S0929664612001441
work_keys_str_mv AT jurshancheng biosignaturescomparativeeffectivenessresearchinbiomarkerclinicalstudies
AT davidbinshiunwu biosignaturescomparativeeffectivenessresearchinbiomarkerclinicalstudies
AT yuwenwen biosignaturescomparativeeffectivenessresearchinbiomarkerclinicalstudies
AT pihualiu biosignaturescomparativeeffectivenessresearchinbiomarkerclinicalstudies
AT jrrunglin biosignaturescomparativeeffectivenessresearchinbiomarkerclinicalstudies
AT cheejenchang biosignaturescomparativeeffectivenessresearchinbiomarkerclinicalstudies
_version_ 1725623316020985856